Beruflich Dokumente
Kultur Dokumente
Pengembangan Obat
Drug discovery
Prof.Dr.dr. M T Kamaluddin,M.Sc.,SpFK
Bagian Farmakologi
Fakultas Kedokteran Unsri
2017
Man and Nature were interdependent
6. In cases where medicines are needed where significant numbers of patients have
higher incomes, there is disproportionate emphasis on products that do not provide
incremental benefits over existing ones. A breakdown of the 1,035 new drugs
approved by the US FDA (Federal Drug Administration) between 1989 and 2000
revealed that more than are classed as having no therapeutic benefit over existing
products, so called me too drugs (NIHCM 2002). At the same time it was noted that
less than 1% addressed diseases that primarily afflict the poor and for which new
treatments would have the greatest effect on world healthcare (WHO 2003)
100
120
140
160
180
200
20
40
60
80
Source: Kaiser Permanente, the largest HMO in America
150.000 Stroke
WHO ARE WE?
ONVENTIONAL
DISEASE
SAKIT NON CONVENTION
Pathogenese
Naturopathic Medicine
Anti Aging Medicine
DIS-EASE Wellness Medicine
SEHAT Regenerative Medicine
Physiogenese Functional Medicine
Restorative Medicine
PHYSIOGENESIS TARGET
Conventional
Disease only treat the
PATHOGENESE
symptoms
Symptoms
Imbalances
biological Symptoms are
function caused by
imbalances in
Dis-ease the body
PHYSIOGENESE
To find the
The Person cause you
have to look
at the person
holisticly
HEALTH & MEDICAL CARE GRADING
TREATMENT
RECOVERY
REJUVENATION
REVITALIZATION
Target selection & Discovery Development
validation
Animal Studies
- relevant species Drug Approval
- transgenic KO/KI mice Lead optimization and Registration
-selectivity
- conditional KOs
-efficacy in animal models
- agonists/antagonists
-tolerability: AEs mechanism-
- antibodies based or structure-based?
- antisense -pharmacokinetics
- RNAi -highly iterative process
Target Selection & Validation
Pharmaceutical R&D
Formulation Bio Process R&D
Clinical Investigator
& patient
Regulatory Affairs
Clinical Pharmacology Project Planning & Management
Clinical Research Marketing
Clinical Phase II
Trials Several hundred health-impaired patients Information Learned
1. Effectiveness in treating disease
Treatment Group Control Group
2. Short-term side effects in health -impaired patients
3. Dose range
Compassionate Use
Clinical Advisory
Committee Regulatory
Trials Review Team
Continued
APPROVAL
Reviews,
PROCESS comments, and
(Ex. FDA)
discussions
Submit to
Regulatory Agencies
Drug Co./Regulatory
liaison activities
New Drug
Application
(NDA)
APPROVAL
Physiology
Safety
Pharmacodynami Physiology
Metabolism cs
Pharmacology
Safety Properties
Assessment Immunolo
In Vivo activity Pharmacokinetic gy
Properties DMP
K
Pharmacology Behavior
Pathology
Physiolog Physical Physiology Enzymology
Chemistry
y
Conventional Medicine
HEALTHY SICK
The aspects: You are either healthy or sick. If you are healthy you do not require
medication. If you are sick you generally will be given a prescription to control
whatever symptoms you might have
Functional Medicine
HEALTHY Vital force SICK
The goal is to restore important function within your body. If you treat the cause
of the problem, you can prevent it from developing into the full blown disease.
Treating is important but prevent relapsing is more more important
Patient centered-care
A dynamic balance
Homeostasis vs Homeodynamics
HOMEOSTASIS HOMEODYNAMICS
Y Y Y
DNA
Transporter - Replication
- Transcription
- DNA repair
Protein
Ion Mitochondrion
biosynthesis
channels
n
u
c
l RNA
e
u
Enzymes s
lysosome
Cell membrane
Posttranslational
Cytoskeleton protein modification
(actin, microtubules)
Van Wyk (2004)
DIS-